Observational studyBMC cancer2025
Low overall survival after treatment for angiosarcoma: a single-centre retrospective observational cohort study of 64 patients.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diagnostic Pitfall in Cardiac Angiosarcoma: Initial Misdiagnosis as Masson Tumor Due to Sampling of Necrotic Tissue.Reports (MDPI) · 2026Article
- Article
- Incidence and Survival of Thoracic Angiosarcoma: Epidemiologic Evidence from a Population-Based Cancer Registry.Cancers · 2026Article
- Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAngiosarcoma (AS), a rare and highly malignant tumour, can manifest spontaneously (primary AS, pAS) or secondary to previous radiation, exposure to chemical agents or Stewart-Treves syndrome (secondary AS, sAS). The aim of this study was to characterise the clinical presentation, management, treatment and outcome-including local recurrence, metastasis and overall survival-among patients diagnosed with AS and treated at Sahlgrenska University Hospital, Gothenburg, Sweden. STUDY METHODS AND
designThis is a retrospective single-centre study analysing patients treated for AS at Sahlgrenska University Hospital. Patients were identified over a 21-year period (1 January 2000 to 31 December 2020) using Systematised Nomenclature of Medicine (SNOMED) code M91203. Medical records for all patients were reviewed by the authors.
resultsThe study identified 64 patients with AS. The mean age among all patients was 67 (SD 16.6 range 18-96) years. The cohort comprised 37 patients diagnosed with pAS and 27 patients with sAS. Of the patients diagnosed with pAS, 18 (48.6%) were women while 25 (92.6%) women were diagnosed with sAS. Fifty-four (84%) patients were treated with surgery and 34 (63%) with adjuvant chemotherapy, radiation, or both. Local recurrence after primary surgery was 65.4% in pAS and 63% for sAS patients. Upon study completion, 15 (23%) patients were alive. Thirty-nine (60.9%) patients died of AS, while 10 (15.6%) died of other diseases or undetermined causes. Five-year overall survival rates were 10.2% and 43.5% in the pAS and sAS groups, respectively.
conclusionpASs are observed in both men and women, presenting at different locations in the body. In contrast, the majority of sASs arise in the thoracic region in women previously treated for breast cancer. The study shows a 60% local recurrence rate across both pAS and sAS groups, yielding 5-year overall survival rates of 10.2% and 43.5% in the pAS and sAS groups, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.